Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
07:30am, Monday, 19'th Aug 2024
PALO ALTO, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, and QED Therapeutics,
BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
02:57am, Saturday, 17'th Aug 2024
BridgeBio Pharma focuses on developing therapies for genetic diseases with a threefold approach to managing costs and timelines effectively. The company employs a threefold R&D strategy: streamlined d
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Thursday, 08'th Aug 2024
PALO ALTO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic disea
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
09:40am, Thursday, 01'st Aug 2024
BridgeBio Pharma (BBIO) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $0.98 per share a year ago.
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
07:30am, Thursday, 01'st Aug 2024
PALO ALTO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases, today r
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
12:27pm, Friday, 26'th Jul 2024
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
08:57pm, Wednesday, 24'th Jul 2024
NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are adv
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
05:10pm, Tuesday, 23'rd Jul 2024
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ:BBIO). Such investors are advi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
10:49am, Saturday, 20'th Jul 2024
NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
09:37pm, Thursday, 18'th Jul 2024
NEW YORK , July 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are advise
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
12:00pm, Sunday, 14'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ:BBIO). Such investors are advi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
12:33pm, Friday, 12'th Jul 2024
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
06:38pm, Wednesday, 10'th Jul 2024
NEW YORK , July 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are advis
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
02:33pm, Sunday, 07'th Jul 2024
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such inves
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:31pm, Friday, 05'th Jul 2024
PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic disea
